Legend Biotech
Legend Biotech Corporation, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology.
With a focus on CAR-T cell therapies, Legend Biotech's flagship product, cilta-cel, has garnered significant attention for its unique approach to treating multiple myeloma. The company operates primarily in the US and has expanded its reach into key international markets, enhancing its global footprint.
Recognised for its commitment to advancing healthcare, Legend Biotech has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its position as a trailblazer in the biopharmaceutical landscape.
+19 vs industry average
Legend Biotech’s score of 57 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Legend Biotech?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Legend Biotech's reported carbon emissions
Legend Biotech, a pharmaceutical preparation manufacturer headquartered in the US, reported approximately 12.7 million kg CO2e of Scope 1 and 2 emissions in 2024. This figure is comprised of about 769,000 kg CO2e from Scope 1 and approximately 11.9 million kg CO2e from Scope 2 (market-based). For the preceding year, 2023, Legend Biotech reported total Scope 1 and 2 emissions of about 13.0 million kg CO2e, with Scope 1 emissions at approximately 770,000 kg CO2e and Scope 2 (market-based) emissions at about 12.2 million kg CO2e.
Legend Biotech's emissions data is cascaded from Genscript Biotech Corporation. The company has disclosed Scope 1 and 2 emissions data but has not yet reported Scope 3 emissions. There are no specific reduction targets or achievements detailed for Legend Biotech itself, but its climate initiatives are informed by its parent organisation, Genscript Biotech Corporation, particularly concerning SBTi and RTZ initiatives.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Legend Biotech’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Legend Biotech yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Legend Biotech
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project